123 related articles for article (PubMed ID: 36183312)
1. Serum ADAM metallopeptidase domain 12 as a promising diagnostic biomarker for breast and liver cancer.
Wang H; Wu H; Chen Y
Clin Transl Oncol; 2023 Feb; 25(2):473-481. PubMed ID: 36183312
[TBL] [Abstract][Full Text] [Related]
2. ADAM12 expression predicts clinical outcome in estrogen receptor-positive breast cancer.
Ma B; Ma Q; Jin C; Wang X; Zhang G; Zhang H; Seeger H; Mueck AO
Int J Clin Exp Pathol; 2015; 8(10):13279-83. PubMed ID: 26722530
[TBL] [Abstract][Full Text] [Related]
3. ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer.
Duhachek-Muggy S; Zolkiewska A
BMC Cancer; 2015 Mar; 15():93. PubMed ID: 25886595
[TBL] [Abstract][Full Text] [Related]
4. A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma.
Mino N; Miyahara R; Nakayama E; Takahashi T; Takahashi A; Iwakiri S; Sonobe M; Okubo K; Hirata T; Sehara A; Date H
J Surg Oncol; 2009 Sep; 100(3):267-72. PubMed ID: 19544357
[TBL] [Abstract][Full Text] [Related]
5. ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.
Cheon DJ; Li AJ; Beach JA; Walts AE; Tran H; Lester J; Karlan BY; Orsulic S
Carcinogenesis; 2015 Jul; 36(7):739-47. PubMed ID: 25926422
[TBL] [Abstract][Full Text] [Related]
6. ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors.
Narita D; Seclaman E; Ilina R; Cireap N; Ursoniu S; Anghel A
Pathol Oncol Res; 2011 Jun; 17(2):375-85. PubMed ID: 21240579
[TBL] [Abstract][Full Text] [Related]
7. Upregulated expression of ADAM12 is associated with progression of oral squamous cell carcinoma.
Uehara E; Shiiba M; Shinozuka K; Saito K; Kouzu Y; Koike H; Kasamatsu A; Sakamoto Y; Ogawara K; Uzawa K; Tanzawa H
Int J Oncol; 2012 May; 40(5):1414-22. PubMed ID: 22267082
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of ADAM12 in human bladder cancer.
Fröhlich C; Albrechtsen R; Dyrskjøt L; Rudkjaer L; Ørntoft TF; Wewer UM
Clin Cancer Res; 2006 Dec; 12(24):7359-68. PubMed ID: 17189408
[TBL] [Abstract][Full Text] [Related]
9. Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12.
Stautz D; Wewer UM; Kveiborg M
PLoS One; 2012; 7(5):e37628. PubMed ID: 22662180
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of ADAM12 gene in breast cancers.
Nariţa D; Anghel A; Seclaman E; Ilina R; Cireap N; Ursoniu S
Rom J Morphol Embryol; 2010; 51(4):669-76. PubMed ID: 21103624
[TBL] [Abstract][Full Text] [Related]
11. ADAM12 induces estrogen-independence in breast cancer cells.
Roy R; Moses MA
Breast Cancer Res Treat; 2012 Feb; 131(3):731-41. PubMed ID: 21387162
[TBL] [Abstract][Full Text] [Related]
12. Increased ADAM12 Expression Predicts Poor Prognosis in Cervical Cancer Patients before General Anesthesia.
Ma X; Wu Z; Zhang J; Shao X; Shen H
Clin Lab; 2021 Feb; 67(2):. PubMed ID: 33616346
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic diversity of breast cancer-related mutations in metalloproteinase-disintegrin ADAM12.
Qi Y; Duhachek-Muggy S; Li H; Zolkiewska A
PLoS One; 2014; 9(3):e92536. PubMed ID: 24651654
[TBL] [Abstract][Full Text] [Related]
14. ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma.
Gao J; Yang D; Xu H; Yang K; Ma J; Xia J; Pan X
Bioengineered; 2022 Feb; 13(2):2412-2429. PubMed ID: 35094638
[TBL] [Abstract][Full Text] [Related]
15. Effects of nitric oxide synthase deficiency on a disintegrin and metalloproteinase domain-containing protein 12 expression in mouse brain samples.
Lendeckel U; Wolke C; Bernstein HG; Keilhoff G
Mol Med Rep; 2015 Aug; 12(2):2253-62. PubMed ID: 25892053
[TBL] [Abstract][Full Text] [Related]
16. ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression.
Fröhlich C; Nehammer C; Albrechtsen R; Kronqvist P; Kveiborg M; Sehara-Fujisawa A; Mercurio AM; Wewer UM
Mol Cancer Res; 2011 Nov; 9(11):1449-61. PubMed ID: 21875931
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein.
Dyczynska E; Syta E; Sun D; Zolkiewska A
Int J Cancer; 2008 Jun; 122(11):2634-40. PubMed ID: 18241035
[TBL] [Abstract][Full Text] [Related]
18. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
19. EMMPRIN and ADAM12 in prostate cancer: preliminary results of a prospective study.
Bilgin Doğru E; Dizdar Y; Akşit E; Ural F; Şanlı Ö; Yasasever V
Tumour Biol; 2014 Nov; 35(11):11647-53. PubMed ID: 25139103
[TBL] [Abstract][Full Text] [Related]
20. A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.
Nyren-Erickson EK; Jones JM; Srivastava DK; Mallik S
Biochim Biophys Acta; 2013 Oct; 1830(10):4445-55. PubMed ID: 23680494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
